Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:975927.
doi: 10.1155/2014/975927. Epub 2014 Feb 4.

The prevention of postmenopausal osteoporotic fractures: results of the Health Technology Assessment of a new antiosteoporotic drug

Chiara de Waure  1 , Maria Lucia Specchia  1 , Chiara Cadeddu  1 , Silvio Capizzi  1 , Stefano Capri  1 , Maria Luisa Di Pietro  1 , Maria Assunta Veneziano  1 , Maria Rosaria Gualano  1 , Flavia Kheiraoui  1 , Giuseppe La Torre  1 , Nicola Nicolotti  1 , Antonella Sferrazza  1 , Walter Ricciardi  1
Affiliations

The prevention of postmenopausal osteoporotic fractures: results of the Health Technology Assessment of a new antiosteoporotic drug

Chiara de Waure et al. Biomed Res Int. 2014.

Abstract

Objective: The Health Technology Assessment (HTA) approach was applied to denosumab in the prevention of osteoporotic fractures in postmenopausal women.

Method: Epidemiological, clinical, technical, economic, organizational, and ethical aspects were considered. Medical electronic databases were accessed to evaluate osteoporosis epidemiology and therapeutical approaches. A budget impact and a cost-effectiveness analyses were performed to assess economic implications. Clinical benefits and patient needs were considered with respect to organizational and ethical evaluation.

Results: In Italy around four millions women are affected by osteoporosis and have a higher risk for fractures with 70,000 women being hospitalized every year. Bisphosphonates and strontium ranelate are recommended as first line treatment for the prevention of osteoporotic fractures. Denosumab is effective in reducing vertebral, nonvertebral, and hip/femoral fractures with an advantage of being administered subcutaneously every six months. The budget impact analysis estimated a reduction in costs for the National Health Service with the introduction of denosumab. Furthermore, the economic analysis demonstrated that denosumab is cost-effective in comparison to oral bisphosphonates and strontium ranelate. Denosumab can be administered in outpatients by involving General Practitioners in the management. Ethical evaluation is positive because of its efficacy and compliance.

Conclusion: Denosumab could add value in the prevention of osteoporotic fractures.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Markov model.
See this image and copyright information in PMC

References

    1. Schuiling KD, Robinia K, Nye R. Osteoporosis update. Journal of Midwifery and Women’s Health. 2011;56(6):615–627. - PubMed
    1. Cheng H, Gary LC, Curtis JR, et al. Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare data. Osteoporosis International. 2009;20(9):1507–1515. - PMC - PubMed
    1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. Journal of Bone and Mineral Research. 2007;22(3):465–475. - PubMed
    1. Greendale GA, Barrett-Connor E. Outcomes of osteoporotic fractures. In: Marcus R, Freedman D, Kelsey J, editors. Osteoporosis. Orlando, Fla, USA: Academy Press; 1996.
    1. American Academy of Orthopaedic Surgeons. Position Statement: Osteoporosis/Bone Health in Adults as a National Public Health Priority, 2009, http://www.aaos.org/about/papers/position/1113.asp.

Publication types

MeSH terms

Substances

LinkOut - more resources